143 related articles for article (PubMed ID: 37798164)
1. TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis.
Pisano C; Turco F; Arnaudo E; Fea E; Vanella P; Ruatta F; Filippi R; Brusa F; Prati V; Vana F; Mennitto A; Cattrini C; Vignani F; Dionisio R; Icardi M; Guglielmini P; Buosi R; Stevani I; Vormola R; Numico G; Depetris I; Comandone A; Gennari A; Airoldi M; Rossi M; Vellani G; Ortega C; Tucci M; Maio MD; Buttigliero C
Clin Genitourin Cancer; 2024 Apr; 22(2):56-67.e16. PubMed ID: 37798164
[TBL] [Abstract][Full Text] [Related]
2. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer.
Lam BHW; Tsang VHM; Lee MP; Chan K; Liu TC; Ng BYH; Wo BBW; Leung KC; Mui WH; Chan TW; Lam MHC; Siu SWK; Poon DMC
Clin Genitourin Cancer; 2024 Feb; 22(1):e75-e85.e1. PubMed ID: 37604745
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
Lambert E; Hollebosch S; van Praet C; Van Bruwaene S; Duck L; De Roock W; van Wambeke S; Ghysel C; Ameye F; Schatteman P; Vandenbroucke F; Sautois B; Baekelandt F; Ost D; Fransis K; Filleul B; Remondo C; Wynendaele W; Bamelis B; Logghe P; Vergauwe E; Denies E; Joniau S; Lumen N
Acta Clin Belg; 2022 Dec; 77(6):897-905. PubMed ID: 34789066
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis.
Guo Z; Lu X; Yang F; Qin L; Yang N; Wu J; Wang H
Eur J Med Res; 2022 Aug; 27(1):148. PubMed ID: 35953852
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.
Fallara G; Robesti D; Nocera L; Raggi D; Marandino L; Belladelli F; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
Cancer Treat Rev; 2022 Nov; 110():102441. PubMed ID: 35939976
[TBL] [Abstract][Full Text] [Related]
6. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
[TBL] [Abstract][Full Text] [Related]
7. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.
Hoeh B; Garcia CC; Wenzel M; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH; Mandel P
Eur Urol Focus; 2023 Sep; 9(5):838-842. PubMed ID: 37055323
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T
Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
[TBL] [Abstract][Full Text] [Related]
9. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Harshman LC; Chen YH; Liu G; Carducci MA; Jarrard D; Dreicer R; Hahn N; Garcia JA; Hussain M; Shevrin D; Eisenberger M; Kohli M; Plimack ER; Cooney M; Vogelzang NJ; Picus J; Dipaola R; Sweeney CJ;
J Clin Oncol; 2018 Feb; 36(4):376-382. PubMed ID: 29261442
[TBL] [Abstract][Full Text] [Related]
10. Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan.
Muto Y; Narita S; Hatakeyama S; Maita S; Chiba S; Kubo K; Aoyama Y; Ito R; Takahashi Y; Takahashi S; Nakamura K; Honma N; Sato H; Koizumi A; Igarashi R; Okane K; Ishida T; Horikawa Y; Kumazawa T; Akihama S; Shimoda J; Suzuki T; Ohyama C; Habuchi T
Med Oncol; 2021 Mar; 38(4):37. PubMed ID: 33713196
[TBL] [Abstract][Full Text] [Related]
11. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
12. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice.
Park K; Kim JY; Park I; Shin SH; Lee HJ; Lee JL
Yonsei Med J; 2023 Feb; 64(2):86-93. PubMed ID: 36719015
[TBL] [Abstract][Full Text] [Related]
14. Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.
Kafka M; Burtscher T; Fritz J; Schmitz M; Bektic J; Ladurner M; Horninger W; Heidegger I
World J Urol; 2023 Aug; 41(8):2043-2050. PubMed ID: 36287244
[TBL] [Abstract][Full Text] [Related]
15. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
Oudard S; Latorzeff I; Caty A; Miglianico L; Sevin E; Hardy-Bessard AC; Delva R; Rolland F; Mouret L; Priou F; Beuzeboc P; Gravis G; Linassier C; Gomez P; Voog E; Muracciole X; Abraham C; Banu E; Ferrero JM; Ravaud A; Krakowski I; Lagrange JL; Deplanque G; Zylberait D; Bozec L; Houede N; Culine S; Elaidi R
JAMA Oncol; 2019 May; 5(5):623-632. PubMed ID: 30703190
[TBL] [Abstract][Full Text] [Related]
16. Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.
Fiorica F; Buttigliero C; Grigolato D; Muraro M; Turco F; Munoz F; Tucci M
Curr Oncol; 2022 Dec; 29(12):9511-9524. PubMed ID: 36547161
[TBL] [Abstract][Full Text] [Related]
17. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Mori K; Sano T; Otsuka T; Iwamoto Y; Enei Y; Nakazono M; Sakanaka K; Iwatani K; Matsukawa A; Atsuta M; Nishikawa H; Tsuzuki S; Miki J; Habuchi T; Ohyama C; Shariat SF; Egawa S
World J Urol; 2023 Aug; 41(8):2051-2062. PubMed ID: 35596809
[TBL] [Abstract][Full Text] [Related]
18. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
19. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
Wenzel M; Hoeh B; Chun FKH; Mandel P
Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
[TBL] [Abstract][Full Text] [Related]
20. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
